The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
The Abortion in the United States Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade. It features a continuously-updated map tracking the status of abortion bans across the United States, as well as briefs on topics such as medication abortion, insurance coverage, ballot measures, legal developments, and racial and ethnic disparities. It also offers a jumping off point to the latest national and state-specific abortion policies and statistics. Visit the Dashboard →
Access to medication abortion has emerged as a central issue following the Dobbs decision overturning Roe v. Wade. There is ongoing litigation in four federal cases about the FDA’s approval and regulation of mifepristone, one of the two drugs used in medication abortion. Mifepristone, approved by the FDA in 2000, has a long record of safety and effectiveness and has been used by more than 5 million people in the United States. In the most…
KFF has created two new trackers to follow swift-moving reproductive rights litigation in the state and federal courts. The tools, which are currently tracking the status of 21 state cases in 15 states and eight federal cases, will be updated regularly as the litigation proceeds. Major cases pending in federal and state courts could impact access to abortion and contraceptive care for millions across the US. In fact, a federal district court is considering a…
More than six months since the Supreme Court issued their Dobbs decision which overturned Roe v. Wade, there is widespread public confusion about the medication abortion pill and whether it is legal at the state level, according to the latest KFF Health Tracking Poll. The poll also finds many are unsure about the legality of emergency contraceptive pills, sometimes called morning after pills or “Plan B,” and whether the pills can end a pregnancy. Across…
Following the FDA approval of retail pharmacies carrying and distributing medication abortion, this poll finds that the public's awareness and knowledge of emergency contraception and medication abortion is still lacking, especially among respondents living in states with full abortion bans.
As the nation marks the 50th anniversary of the Supreme Court of the United States landmark Roe v. Wade decision, which the Supreme Court overturned, 14 states have active litigation challenging state abortion bans and restrictions. A new KFF brief explains how individuals and organizations suing to block the bans are framing their legal challenges based on different state constitutional protections and state laws now that the battleground over abortion rights rests with states. The…
This issue brief presents an overview of the legal challenges presented in state courts since the Dobbs ruling in June 2022 and highlights some of the novel strategies that are being used to defend access to abortion in states that have enacted abortion bans.
This survey looks at the public's health care priorities for the new Congress, including price transparency, mental health, abortion, Medicaid, and health costs. It also looks at the public's views of the main health provisions in the Inflation Reduction Act (IRA), including on Medicare drug prices.
On December 13th, KFF held a web event highlighting key findings from KFF’s 2022 Women’s Health Survey on women’s contraceptive access, experiences, and preferences. After the presentation of the survey findings, leaders in sexual and reproductive health care explored the challenges and opportunities in contraceptive care access in a rapidly changing policy and clinical context.
This analysis uses the 2019 IBM MarketScan claims data to look at prescriptions of methotrexate and misoprostol, two drugs that can be used to terminate pregnancies, but are also used to manage chronic conditions like cancer, autoimmune diseases, and abnormal bleeding. These drugs may be restricted in response to state abortion bans, which we find will disproportionately affect women of reproductive age who make up the majority of those who rely on these drugs.
A new KFF analysis finds that women comprise the majority of patients who rely on certain drugs that may be restricted in response to state abortion bans. Following the Supreme Court decision to overturn Roe v. Wade, some women in abortion-banning states have reported that clinicians and pharmacists denied them access to medications like methotrexate and misoprostol that are used to manage chronic conditions but are also used for medication abortions and treatment of ectopic…
© 2026 KFF